In Genzyme Limited v. OFT, 29 September 2005, the UK Competition Appeal Tribunal (the “CAT”) tackled the difficult question of how to bring an abusive margin squeeze to an end and to ensure it was not repeated. The background to the proceedings was that the OFT had issued a decision (Director General of Fair Trading, 27 March 2003, Decision n° CA98/3/03, Exclusionary behaviour by Genzyme Limited, Case CP/0488-01) finding that Genzyme had, since 2001, abused its dominant position contrary to the UK Competition Act 1998 Chapter II prohibition (Chapter II is
The UK Competition Appeal Tribunal issues a key judgment on margin squeeze and rebates in the pharmaceutical sector (Healthcare at Home / Genzyme)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.